Fresenius Medical Care 5008 Therapy System Supports New Study That Shows Hemodiafiltration Reduces Mortality for Patients with Chronic Kidney Disease by 35 Percent

Fresenius Medical Care offers online-hemodiafiltration(HDF) as standard treatment as part of its new 5008 Therapy System forthe first time. Until now, increased costs made online-HDF viable foronly a few patients. With the 5008, operating costs have beensignificantly reduced through simpler user-interfaces, lowermaintenance effort and as much as 30 percent reduction in electricityand water usage. Now, more dialysis patients can be provided withonline-HDF. Fresenius Medical Care was presented with the GermanBusiness Innovation Award at the start of the year for the 5008Therapy System.

The mortality rate among patients with kidney disease issignificantly lower with hemodiafiltration than with conventionalhemodialysis. This is the result of a new study

conducted by specialists at the University Hospital in Lapeyroniein Montpellier and led by French nephrology professor Bernard Canaud.The study showed that kidney patients treated with high-efficiencyhemodiafiltration therapy had a 35 percent better chance of survivalthan those that received traditional hemodialysis. The three-yearDialysis Outcomes and Practice Patterns Study (DOPPS) from fiveEuropean countries involved 2,165 patients who received treatment anaverage of three times per week.

This is the first time a prospective observational study, adjustedto exclude influencing factors such as age and multiple illnesses,proved that HDF treatment has reduced mortality rates among patientswith chronic kidney disease. A retrospective study published last yearand using existing data had already provided the first indications ofthe positive effects of HDF. Specialists attribute the improvedsurvival rates with the HDF therapy to a more efficient removal ofharmful substances from the blood, less side-effects and a loweroverall risk of cardiovascular illness. Cardiovascular complicationsremain the most common cause of mortality among dialysis patients andare responsible for almost every second death.

Dr. Emanuele Gatti, Fresenius Medical Care Management Board Memberresponsible for Europe, Latin America, the Middle East and Africa:"The positive results of the new study support our efforts to provideinnovative treatment methods such as hemodiafiltration to allowpatients with chronic kidney failure to look confidently towards thefuture. We expect the demand for online-HDF to continue growing."

Online-hemodiafiltration combines two different methods of removalof toxins: diffusion-based hemodialysis, and hemofiltration wherebyblood is filtered through a membrane. HDF is particularly efficientand gentle when filtering toxins and removing water from the patient'sblood. The 5008 Therapy System automatically replaces the fluidremoved with an appropriate quantity of ultrapure electrolytesolution; the solution is prepared by the dialysis machine "online",eliminating the need for additional infusion solutions in bags.

The study has been published in the online-edition of "Kidneyinternational" at:http://www.nature.com/ki/journal/vaop/ncurrent/full/5000447a.html.

Fresenius Medical Care is the world's largest, integrated providerof products and services for individuals undergoing dialysis becauseof chronic kidney failure, a condition that affects more than1,400,000 individuals worldwide. Through its network of approximately2,000 dialysis clinics in North America, Europe, Latin America,Asia-Pacific and Africa, Fresenius Medical Care provides dialysistreatment to approximately 157,000 patients around the globe.Fresenius Medical Care is also the world's leading provider ofdialysis products such as hemodialysis machines, dialyzers and relateddisposable products. Fresenius Medical Care is listed on the FrankfurtStock Exchange (FME, FME3) and the New York Stock Exchange (FMS,FMS-p).

For more information about Fresenius Medical Care visit theCompany's website at www.fmc-ag.com.

This release contains forward-looking statements that are subjectto various risks and uncertainties. Actual results could differmaterially from those described in these forward-looking statementsdue to certain factors, including changes in business, economic andcompetitive conditions, regulatory reforms, foreign exchange ratefluctuations, uncertainties in litigation or investigativeproceedings, and the availability of financing. These and other risksand uncertainties are detailed in Fresenius Medical Care AG & Co.KGaA's reports filed with the U.S. Securities and Exchange Commission.Fresenius Medical Care AG & Co. KGaA does not undertake anyresponsibility to update the forward-looking statements in thisrelease.